As a result of its role in the regulation, activation and migration of inflammatory cells, Sema4D is the target of a therapeutic antibody (VX15/2503, Vaccinex Inc.)currently in phase I clinical trials for patients with multiple sclerosis (ClinicalTrials.gov identifier: NCT01764737). The gene discussed is SEMA4D; the disease is multiple sclerosis.